BioCardia (NASDAQ:BCDA) Director Simon Stertzer Purchases 39,000 Shares

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer bought 39,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were bought at an average price of $1.00 per share, for a total transaction of $39,000.00. Following the transaction, the director owned 166,338 shares of the company’s stock, valued at approximately $166,338. This represents a 30.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

BioCardia Stock Performance

Shares of BCDA stock traded up $0.06 during trading hours on Wednesday, reaching $1.06. The company had a trading volume of 489,451 shares, compared to its average volume of 1,516,771. The business has a fifty day moving average price of $1.02 and a 200-day moving average price of $1.18. The firm has a market cap of $12.06 million, a PE ratio of -1.16 and a beta of 0.51. BioCardia, Inc. has a one year low of $0.78 and a one year high of $2.45.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Equities research analysts forecast that BioCardia, Inc. will post -0.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on BCDA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of BioCardia in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BioCardia has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BCDA. DRW Securities LLC acquired a new position in shares of BioCardia during the 4th quarter worth approximately $72,000. Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after buying an additional 27,263 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in BioCardia during the second quarter valued at approximately $40,000. 20.57% of the stock is currently owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.